Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Change in Accured Expenses for 6 consecutive years, with $718197.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 466.18% to $718197.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 393.14% increase, with the full-year FY2024 number at $420075.0, up 403.34% from a year prior.
  • Change in Accured Expenses was $718197.0 for Q3 2025 at Inhibikase Therapeutics, up from -$575063.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.0 million in Q3 2021 to a low of -$1.3 million in Q3 2022.
  • A 5-year average of $159128.9 and a median of $245372.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 15605.69% in 2022, then crashed 273.47% in 2024.
  • Inhibikase Therapeutics' Change in Accured Expenses stood at $810751.0 in 2021, then crashed by 83.67% to $132394.0 in 2022, then soared by 203.44% to $401740.0 in 2023, then grew by 29.1% to $518656.0 in 2024, then soared by 38.47% to $718197.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Change in Accured Expenses are $718197.0 (Q3 2025), -$575063.0 (Q2 2025), and $833219.0 (Q1 2025).